-

Schrödinger to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference. The presentation will take place virtually on Tuesday, May 11, 2021, at 3:30 pm. ET.

The live webcast can be accessed under "News & Events" in the investors section of Schrödinger’s website, https://ir.schrodinger.com/news-and-events/event-calendar and will be archived for approximately 14 days.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Stephanie Simon (media)
Ten Bridge Communications
617-581-9333

Industry:

Schrödinger

NASDAQ:SDGR
Release Summary
Schrödinger today announced that it will participate in the Bank of America Securities 2021 Virtual Healthcare Conference.
Release Versions
English

Contacts

Jaren Irene Madden
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264

Stephanie Simon (media)
Ten Bridge Communications
617-581-9333

More News From Schrödinger

Schrödinger Announces Licensing and Collaboration Agreement with Tectora Therapeutics, a New Biotechnology Company It Co-founded to Advance Immunology and Inflammation Programs

NEW YORK--(BUSINESS WIRE)--Schrödinger announced the formation of Tectora, a biotech it co-founded with NEA and RA Capital, focused on immunology and inflammation therapies....

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The live presentation will take place on Monday, September 14, 2026 at 1:05 p.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery wi...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement t...
Back to Newsroom